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Abstract
Introduction: The aim of this study was to evaluate beta-cell function and insulin resistance in relation to the occurrence of anti-islet 
antibodies in first degree relatives of patients with type 1 diabetes (T1D).
Material and methods: The group studied consisted of 90 relatives and 60 healthy individuals without a family history of diabetes. An 
intravenous glucose tolerance test (IVGTT) was performed in all participants and the first phase insulin response index (FPIR) was cal-
culated. Serum concentrations of GADA, IAA and IA-2A were measured by RIA. HOMA-IR and HOMA%B indices were calculated using 
a computer calculator from website.
Results: At least one positive antibody was found in 28 relatives (31.1%) but in none of the controls. The most frequently detected anti-
bodies were IAA (22.2%). The relatives of diabetic patients had significantly higher fasting insulin level (p), significantly lower FPIR index 
(p), as well as higher HOMA-IR (p) and lower HOMA%B (p) compared to the controls. A positive correlation between IAA concentration 
and HOMA-IR (r = 0.287, p < 0.005) and a negative correlation between IAA level and HOMA%B (r = –0.226, p < 0.05) were also shown.
Conclusions: Our results confirmed that more than 30% of the first-degree relatives of diabetic patients have positive markers of autoim-
mune beta-cell destruction. The study showed also that these individuals, in spite of normal glucose tolerance, have markedly decreased 
beta-cell secretory reserve and decreased sensitivity to insulin action, strongly suggesting an increased risk for developing diabetes later 
in life. (Endokrynol Pol 2014; 65 (3): 176–180)
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Streszczenie
Wstęp: Celem pracy była ocena funkcji komórek beta i wrażliwości na insulinę w zależności od obecności przeciwciał skierowanych 
przeciwko antygenom wysp trzustkowych, u krewnych I stopnia osób chorych na cukrzycę typu 1 (T1D) 
Materiał i metody: Grupę badaną stanowiło 90 krewnych I stopnia oraz 60 osób z ujemnym wywiadem rodzinnym w kierunku cukrzycy 
(grupa kontrolna). U wszystkich badanych dokonano pomiaru przeciwciał GADA, IAA i IA-2A (RIA), a następnie wykonano dożylny test 
tolerancji glukozy z oceną pierwszej fazy wydzielania insuliny oraz obliczono wskaźniki HOMA-IR i HOMA%B.
Wyniki: Podwyższone stężenie przynajmniej jednego przeciwciała stwierdzono u 28 krewnych (31,1%), przy czym najwyższy odsetek 
dotyczył przeciwciał IAA (22,2%). Obecności przeciwciał przeciwwyspowych nie obserwowano w grupie kontrolnej. W grupie krewnych 
wykazano ponadto istotnie wyższe stężenie insuliny na czczo (p < 0,005), istotnie obniżony wskaźnik pierwszej fazy wydzielania insuliny 
(p < 0,005), jak również znamiennie wyższy wskaźnik HOMA-IR (p < 0,005) i niższy wskaźnik HOMA%B (p < 0,05) w porównaniu z 
grupą kontrolną. Stwierdzono także dodatnią korelację pomiędzy stężeniem IAA i HOMA-IR (r = 0,287, p < 0,005) oraz ujemną pomiędzy 
stężeniem IAA i HOMA%B (r = –0,226, p < 0,05).
Wnioski: Wyniki potwierdzają obecność markerów autoimmunologicznej destrukcji komórek beta u ponad jednej trzeciej krewnych 
pacjentów z cukrzycą typu 1. Krewni I stopnia, pomimo prawidłowej tolerancji glukozy, charakteryzują się zaburzeniami pierwszej fazy 
wydzielania insuliny oraz zmniejszoną wrażliwością na insulinę, co może wskazywać na podwyższone ryzyko rozwoju cukrzycy typu 
1 w przyszłości. (Endokrynol Pol 2014; 65 (3): 176–180)
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Introduction
Type 1 diabetes occurs when autoimmune destruc-
tion of beta cells reaches a stage at which metabolic 
stability is no longer maintained. To date, it is not 
well understood when this autoimmune destruc-
tion begins in relation to the clinical presentation of 
the disease and what screening tests can accurately 
select the subjects who are at risk for developing the 
disease [1]. Moreover, it has been suggested that not 
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only decreased beta-cell secretory reserve but also 
decreased sensitivity to insulin action may impact 
upon the progression of the autoimmune process 
and promote the development of hyperglycaemia in 
subjects with autoantibodies directed against pancre-
atic islet antigens [2]. The assessment of first phase 
insulin secretion together with the measurement of 
antibodies against pancreatic antigens are regarded 
as the most sensitive prognostic indicators of the risk 
for the development of type 1 diabetes, especially in 
genetically predisposed persons and high risk groups, 
such as first degree relatives of patients [3]. The pres-
ence of circulating autoantibodies to glutamic acid 
decarboxylase (GADA), insulin autoantibodies (IAA) 
and autoantibodies to thyrosine phosphatase (IA-
2A), as well as the antibodies that recognise the zinc 
transporter autoantigen (ZnT8) identifies underlying 
islet autoimmune pathology and an increased risk of 
diabetes. This risk has been shown to be related to 
both the number and the levels of islet antibodies, as 
well as to the degree of impaired insulin secretion [5]. 
Moreover, some data shows that the presence of GADA 
and IA-2A in combination has a high specificity and 
sensitivity for the prediction of future clinical onset 
of the disease. IAA are usually the first antibodies that 
appear in the relatives of diabetic patients, especially in 
young children [6–8]. The role of anti-islet antibodies 
and a decline in first-phase insulin response (FPIR) 
in predicting type 1 diabetes has been confirmed by 
the results of The Diabetes Prevention Trial — Type 1 
(DPT-1) [9] but the contribution of impaired insulin 
sensitivity and action to the development of type 1 
diabetes has received little attention so far.
The aim of the present study was to evaluate the 
first phase insulin secretion, as well as insulin resist-
ance measured by HOMA-IR in relation to the presence 
of antibodies against pancreatic islets in first degree 
relatives of patients with type 1 diabetes, and healthy 
individuals without a family history of diabetes.
Material and methods
The group studied consisted of 90 first-degree relatives 
(parents, siblings and offspring) of patients with type 1 
diabetes (48 women and 42 men, mean age 34.4 ± 15.7 
[18–67] years and mean BMI 22.4 ± 4.6 [15.5-38] kg/m2) 
and 60 healthy individuals (36 women and 24 men, 
mean age 32.9 ± 13.7 [18–60] years and mean BMI 
22.8 ± 2.3 [18–26.3] kg/m2) with no family history of 
diabetes or other autoimmunological disorders.
All subjects underwent a 75 g oral glucose toler-
ance test (OGTT) and persons with an abnormal 
result or/and the presence of an autoimmune disease 
were not included. Written informed consent was 
obtained from all participants, and the protocol was 
approved by the local ethics committee (Medical 
University of Bialystok). 
To evaluate the first phase insulin secretion, an 
intravenous glucose tolerance test (IVGTT) was 
performed 5–7 days after the OGTT by intravenous 
administration of 25% glucose solution in a dose of 
0.5 g/kg of body weight (up to 35g) for 3 min (± 15 s). 
Serum insulin levels were measured at 0, 1, 3 and 
5 min. by immunoenzymatic method (BioSource Eu-
rope, S.A., Belgium). The first phase insulin response 
index (FPIR) was calculated as the sum of the serum 
insulin concentrations at 1 and 3 min after intravenous 
glucose administration [5]. Plasma glucose concentra-
tions were measured using oxidase method (CORMAY, 
Poland). HOMA%B (Homeostatic Model Assessment 
of β Cell Function) and HOMA-IR (Homeostatic Model 
Assessment of Insulin Resistance) were calculated us-
ing a computer calculator located at www.OCDEM.
ox.ac.uk (Oxford Centre for Diabetes, Endocrinol-
ogy and Metabolism). Glutamic acid decarboxylase 
antibodies (GADA), insulin autoantibodies (IAA) and 
protein tyrosine phosphatase-2 antibodies (IA-2A) 
were determined by commercial radioimmunoassays 
(CIS Bio International, France). Cut-off values for each 
antibody positivity were calculated as the 99th percen-
tile of antibody level in 350 nondiabetic persons and 
were as follows: 1.0 U/mL for GADA, 9.8 U/mL for IAA 
and 0.75 U/mL for IA-2A.
Statistical analysis was performed using STATIS-
TICA 8.0 software (Statsoft, Tulsa, OK, USA). Before 
analysis, data was tested for normality of distribution 
using the Shapiro-Wilk test. Differences between 
the groups were compared by Mann Whitney U test 
and relationships between variables were tested by 
Pearson’s correlations after log-transformation of non 
normally distributed variables. P value of less than 0.05 
was regarded as statistically significant. 
Results
Clinical characteristics of the groups studied
The clinical and biochemical characteristics of the 
groups studied are summarised in Table I. There were 
no significant differences in mean BMI and fasting 
glucose values between the group of relatives and the 
controls. The relatives of diabetic patients had statis-
tically significantly higher levels of GADA and IAA 
(p < 0.05 and p < 0.0001, respectively), higher HOMA-
IR (p < 0.05), as well as lower HOMA%B (p < 0.05) and 
FPIR index (p < 0.05) than had the controls (Table I). 
At least one positive antibody was found in 
28 relatives (31.1%) and in none of the controls. IAA was 
detected in 17 persons (18.9%), GADA in seven (7.8%) 
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and IA-2A in one subject (1.1%). The presence of two 
antibodies (IAA and GADA) was found in two persons 
and the coexistence of all three antibodies was noted 
in one person.
In the group of relatives, there was a positive correla-
tion between BMI and HOMA-IR (r = 0.19, p < 0.05), 
but no significant correlations between BMI and immu-
nological markers were noted in both groups studied. 
First phase insulin response and islet  
autoimmunity
The relatives of diabetic patients had statistically signifi-
cantly higher fasting insulin concentration (7.7 µIU/mL 
± 4.3 vs. 5.3 µIU/mL ± 2.3 p < 0.005) and statistically 
significantly lower insulin levels at the 1st and 3rd 
mins of the IVGTT (46.2 µIU/mL ± 33.5 vs. 64.3 µIU/mL 
± 34.1, p < 0.01 and 45.9 µIU/mL ± 30.7 vs. 59.7 µIU/mL 
± 24.9, p < 0.005, respectively) than had the controls 
(Fig. 1). Insulin concentration at the 5th min of the test 
was also lower in the study group than in the controls, 
but the difference was not significant (41.9 µIU/mL 
± 29.3 vs. 47.9 µIU/mL ± 22.9, p = 0.05). Statistically 
significantly higher fasting insulin concentrations were 
also observed in the group of relatives with positive 
IAA compared to the subjects without these antibodies 
(9.4 µIU/mL ± 4.3 vs. 7.3 µIU/mL ± 4.2; p < 0.05). In 
the same group, mean insulin concentrations at the 1st, 
3rd, and 5th mins of the IVGTT were lower than in the 
subjects with negative antibodies but the differences 
were not statistically significant. 
The percentage of subjects with positive antibod-
ies was similar in the subgroup with very low ( < 25th 
quartile), low (between 25th and 50th quartile) and 
medium (50th–75th quartile) FPIR index (30.3%) and 
insignificantly lower than in the subgroup with the 
highest ( > 75th quartile) FPIR index (33.3%). In the 
group of relatives, FPIR index correlated positively 
with HOMA%B (r = 0.59, p = 0.0001) and negatively 
with fasting plasma glucose concentration (r = –0.24, 
p = 0.03), but not with the levels of IAA or GADA. 
HOMA indices and islet autoimmunity
HOMA%B index below 100% was found in 41 relatives, 
among whom there were seven persons with the index 
below 50%. A negative correlation between IAA and 
HOMA%B (r = –0.23, p < 0.05) was observed in the 
study group. HOMA-IR index above 1 was found in 
37 relatives, and 11 of them had the index above 2. In 
the group of relatives, HOMA-IR correlated positively 
with IAA concentration (r = 0.29, p < 0.005; Fig. 1) but 
not with other antibodies levels. 
Discussion 
The constant increase in the incidence of type 1 diabe-
tes, observed worldwide, has aroused interest in accu-
Table I. Clinical characteristics of the groups studied
Tabela I. Charakterystyka kliniczna badanych grup
Study group 
n = 90 
mean ± SD 
med. (min.–max.)
Control group 
n = 60 
mean ± SD 
med. (min.–max.)
p
BMI [kg/m2]
Fasting glucose [mg/dL]
GADA [U/mL]
IAA [U/mL]
IA-2A [U/mL]
HOMA%B
HOMAIR
FPIR
22.1 ± 4.9
21.4 (16–38)
86.7 ± 7.3
87.0 (82–91)
6.0 ± 28.7
0.8 (0.6–218.7)
6.9 ± 1.4
6.8 (4.4–13.2)
0.6 ± 0.7
0.6 ( 0.6–0.9)
92.8 ± 29.4
84.2 (64.4–180.0)
1.2 ± 0.6
1.0 (0.3–3.0)
91.9 ± 62.9
78.7 (49.4–128.7)
22.8 ± 2.3
22.8 (18–26)
84.8 ± 5.2
85.5 (80–89)
0.7 ± 0.1
0.7 (0.6–0.9)
4.4 ± 0.8
4.5 (3.1–5.6)
0.6 ± 0.1
0.6 (0.6–0.7)
114.0 ± 47.1
99.5 (37.3–231.8)
0.8 ± 0.3
0.7 (0.5–1.9)
124.1 ± 55.4
108.3 (80.6–171.0)
p = 0.7
p = 0.2
p < 0.05
p < 0.01
p = 0.7
p < 0.01
p < 0.001
p < 0.005
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rate and reliable predictors of the future development 
of the disease. The data from DPT-1 [9] and other trials 
carried out on first degree relatives of patients with 
type 1 diabetes [5–8] has confirmed the prognostic 
value of immunological markers such as GADA, IAA 
and IA-2A. It has been also demonstrated that the 
possibility of identifying persons who would develop 
diabetes later in life increases with the number and 
mean concentration(s) of anti-islet antibodies [10–12]. 
Moreover, a large analysis based on the DPT-1 data [9] 
showed that in first degree relatives of patients with 
type 1 diabetes, the destruction of pancreatic beta cells is 
accompanied by impaired first phase insulin secretion, 
identifying the IVGTT-derived indices, such as FPIR, as 
having a significant predictive accuracy for selecting 
individuals likely to progress to the clinical onset of 
type 1 diabetes within the next five years. 
The present study revealed that the relatives of 
diabetic patients had statistically significantly higher 
levels of GADA and IAA, as well as lower HOMA%B 
and FPIR indices, than had persons with no family 
history of diabetes. Moreover, at least one positive 
antibody was found in 31.1% of the relatives and 
in none of the controls. It is also worth noting that 
nearly 19% of the relatives had elevated levels of 
IAA which are regarded as having the best predic-
tive value. Therefore, it might be hypothesised that 
these individuals are at substantial risk of developing 
type 1 diabetes later in life. Furthermore, a negative 
correlation between IAA and HOMA%B observed 
in the study group seems to confirm the impact of 
the autoimmune process on decreased beta-cell se-
cretory reserve, although no significant association 
between the incidence or/and the levels of anti-islet 
antibodies and the first phase insulin response was 
shown in our study. It should be mentioned that in 
the previous studies an impairment of the first phase 
insulin secretion was more pronounced in individu-
als with the presence of islet autoantibodies [13] and 
that high titres of GADA and IAA were negatively 
associated with the early phase insulin secretion 
indices [14–16]. It is also noteworthy that despite 
lower insulin levels during the IVGTT, the relatives 
of diabetic patients — especially these with positive 
autoantibodies — had significantly higher fasting in-
sulin concentrations and higher HOMA-IR index than 
had the controls. Moreover, a positive correlation 
between IAA levels and HOMA-IR was found in the 
study group, confirming the previous observations 
suggesting that not only decreased beta-cell secretory 
reserve, but also increased insulin resistance, impact 
upon the progression of the autoimmune process, 
especially in subjects with auto-antibodies directed 
against pancreatic islet antigens [17–19]. Abnormal 
sensitivity to insulin in patients with type 1 diabetes 
was shown for the first time by Ginsberg in the 1970s 
[20]. Moreover, the recently published Wilkin’s ‘ac-
celerator hypothesis’ suggests that type 1 and type 2 
diabetes are parts of the same disease, with two key 
accelerators of β-cell loss: autoimmune destruction 
and insulin resistance [21]. However, the possible 
influence of insulin resistance on the progression 
of type 1 diabetes seems still controversial. Ma et al. 
[22] in a large study carried out on first degree rela-
tives of patients with type 1 diabetes observed that 
the presence of autoantibodies had no impact on 
insulin sensitivity, although the disposition index, 
which is a measure of beta-cell response to a given 
insulin sensitivity level, was markedly lower in the 
relatives with positive autoantibodies. Other authors, 
however, have reported that first-degree relatives 
positive for islet antibodies and with insulin resist-
ance progressed most rapidly to diabetes, suggesting 
that better insulin sensitivity might delay develop-
ment of the disease [23–25]. 
Conclusions
In conclusion, although there is no gold standard in pre-
dicting the future development of type 1 diabetes, our 
results confirmed that more than 30% of the first-degree 
relatives of diabetic patients have positive markers of 
autoimmune beta-cell destruction. Furthermore, the 
present study showed that these individuals, in spite 
Figure 1. Correlation between IAA and HOMA-IR in the study 
group
Rycina 1. Korelacja pomiędzy IAA i HOMA-IR w grupie badanej
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of normal glucose tolerance, have markedly decreased 
beta-cell secretory reserve and decreased sensitivity to 
insulin action, strongly suggesting an increased risk for 
developing the disease later in life.
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